Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Sold by Millennium Management LLC

Millennium Management LLC trimmed its stake in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) by 55.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 596,289 shares of the company's stock after selling 727,484 shares during the quarter. Millennium Management LLC owned 1.34% of Werewolf Therapeutics worth $883,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Deutsche Bank AG grew its stake in Werewolf Therapeutics by 450.7% during the 4th quarter. Deutsche Bank AG now owns 101,626 shares of the company's stock worth $150,000 after purchasing an additional 83,172 shares in the last quarter. D. E. Shaw & Co. Inc. purchased a new stake in Werewolf Therapeutics during the 4th quarter worth about $26,000. Bridgeway Capital Management LLC lifted its holdings in Werewolf Therapeutics by 24.4% during the 4th quarter. Bridgeway Capital Management LLC now owns 109,586 shares of the company's stock worth $162,000 after buying an additional 21,500 shares during the last quarter. Jane Street Group LLC lifted its holdings in Werewolf Therapeutics by 261.2% during the 4th quarter. Jane Street Group LLC now owns 54,713 shares of the company's stock worth $81,000 after buying an additional 39,564 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in Werewolf Therapeutics by 7.3% during the 4th quarter. Northern Trust Corp now owns 244,390 shares of the company's stock worth $362,000 after buying an additional 16,640 shares during the last quarter. 64.84% of the stock is owned by institutional investors and hedge funds.

Werewolf Therapeutics Stock Down 6.1%

Werewolf Therapeutics stock opened at $1.23 on Friday. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.60 and a fifty-two week high of $4.18. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. The company has a market capitalization of $55.20 million, a P/E ratio of -0.80 and a beta of 0.66. The stock has a 50-day simple moving average of $0.95 and a 200-day simple moving average of $1.28.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.04. Werewolf Therapeutics had a negative return on equity of 58.83% and a negative net margin of 578.80%. Equities research analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Insider Buying and Selling at Werewolf Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 320,913 shares of Werewolf Therapeutics stock in a transaction on Monday, May 12th. The stock was purchased at an average cost of $0.86 per share, with a total value of $275,985.18. Following the purchase, the director now directly owns 6,021,969 shares in the company, valued at approximately $5,178,893.34. The trade was a 5.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 23.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HOWL. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Werewolf Therapeutics in a report on Wednesday, March 12th. Wedbush reduced their target price on Werewolf Therapeutics from $8.00 to $6.00 and set an "outperform" rating for the company in a report on Friday, May 9th.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

Want to see what other hedge funds are holding HOWL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.